The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Everolimus in bevacizumab-refractory metastatic renal cell carcinoma patients.
Anton Snegovoy
No relevant relationships to disclose
Liudmila V. Manzyuk
No relevant relationships to disclose
Sergey Varlamov
No relevant relationships to disclose
Sufia Safina
No relevant relationships to disclose
Ludmila Gurina
No relevant relationships to disclose
Ilya Tsimafeyeu
Consultant or Advisory Role - Novartis
Research Funding - Novartis